AFM
ADVM

Anson Funds Management’s Adverum Biotechnologies ADVM Stock Holding History

Anson Funds Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8,182
Closed -$144K – 338
2021
Q4 		$144K Buy
+8,182
New +$164K 0.01% 323
2017
Q1 		– Sell
-12,854
Closed -$373K – 49
2016
Q4 		$373K Buy
+12,854
New +$420K 0.12% 49

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Anson Funds Management's ADVM Position: Q1 2022 in Review

Anson Funds Management sold out of Adverum Biotechnologies (ADVM) in Q1 2022, closing a stake of 8,182 shares — an estimated $144K sold.

Anson Funds Management first reported a position in ADVM in Q4 2016 and held it in 2 quarters. The position peaked at $373K in Q4 2016. 92 funds tracked by Wall St. Rank hold ADVM as of Q1 2022.

  • Anson Funds Management reported no remaining Adverum Biotechnologies position as of Q1 2022 after selling out during the quarter.
  • Anson Funds Management sold 8,182 Adverum Biotechnologies shares in Q1 2022, an estimated $144K.
  • Anson Funds Management first reported a position in Adverum Biotechnologies in Q4 2016 and held it in 2 quarters.
  • Anson Funds Management's Adverum Biotechnologies position peaked at $373K in Q4 2016.
  • 92 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2022.

Based on Anson Funds Management's 13F filing for Q1 2022, filed 12 May 2022.